Biogen plans to invest $2B into its RTP manufacturing facilities
Why it matters: Biogen is one of RTP's largest employers with more than 1,500 workers in Durham County. The latest investment will help it expand its manufacturing capabilities in North Carolina.
Between the lines: Investment into pharmaceutical and biotech manufacturing remains on fire in the Triangle, with Biogen representing just the latest in a string of jobs announcements.
The biotechnology company Genentech said earlier this year it plans to add 400 jobs in Holly Springs, and Amgen and Fujifilm Diosynth recently completed manufacturing facilities there as well.
Last year, Novo Nordisk, the Danish maker of drugs like Ozempic, announced a planned $4 billion investment in facilities in Johnston County.
Zoom in: The investment will help the drug maker build its eighth manufacturing facility in North Carolina, Biogen said in a statement. The company makes a variety of treatments, including for multiple sclerosis, and has a pipeline of products being tested for Alzheimer's, Parkinson's and other diseases.
The company declined an interview request, and it was unclear how many jobs could be supported at the new facility. In 2023, the company laid off some workers due to the bumpy launch of an Alzheimer's treatment, Fierce Biotech reported.
The big picture: The Triangle, which the real estate services firm JLL pegs as the fourth-largest life sciences market in the country, has a lower vacancy rate than its larger peers for life science space.
That's primarily due to a combination of the region not building as much as markets like Boston and San Diego since the pandemic, plus a number of biomanufacturing wins, according to Eric Forshee, JLL's executive vice president for life sciences at its Raleigh office.
"North Carolina, especially on the biomanufacturing side, has good affordable land, quality sites, great talent and good incentives," Forshee told Axios.
What's next: Reuters noted that Biogen is one of several drug makers that have announced investments amid the threat of a 200% tariff on imported drugs from the Trump administration, though Biogen's announcement made no mention of tariffs.
It remains to be seen how tariffs could help or hinder biomanufacturing in the Triangle.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
an hour ago
- Scientific American
Ozzy Osbourne's Death Puts Spotlight on Rare Form of Parkinson's
On July 22, Ozzy Osbourne, lead singer of Black Sabbath, died at age 76. The 'Prince of Darkness' had been outspoken about keeping up with stage performances and touring while undergoing care for a rare form of Parkinson's disease called Parkin —named after the gene PRKN which is linked to the disease. He played his last live performance with his bandmates in Birmingham, England on July 5. 'It's been terribly challenging for us all,' Osbourne said in a 2020 Good Morning America interview when he publicly announced his diagnosis. 'There's so many different types of Parkinson's,' Osbourne's wife, Sharon, said during the interview. 'It's not a death sentence by any stretch of the imagination, but it does affect certain nerves in your body.' On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Osbourne's cause of death was not disclosed. The late heavy metal musician had often openly shared his intense lifestyle and experience with drug use, which may have worsened the progression of his form of Parkinson's, according to the New York Times. What Do We Know About Parkin? Parkinson's disease is a neurodegenerative condition in which nerve cells, largely in the basal ganglia of the brain, deteriorate or die. According to the National Institutes of Aging, the illness typically progresses with age (most people develop the disease after age 60) and is known for causing tremors, stiff muscles, balance issues, slowed movement and other mobility problems. People may also experience difficulty swallowing, chewing and speaking as well as mental health issues, including depression and mood changes. Emerging research suggests that acting out dreams might also predict Parkinson's disease. PRKN, which is one of the genes implicated in Parkinson's disease, is involved in maintaining mitochondrial function, which could affect cellular energy—but how that exactly leads to disease is unclear, according to Medline Plus. Parkinson's disease is linked to more than 200 mutations, some of which may cause issues with protein production, durability and function. In the 2020 Good Morning America interview, the Osbourne family disclosed that he had Parkin 2.[LY1] Osbourne had volunteered to have his genome sequenced in 2010 to see if his DNA could offer more clues about his health and condition. 'He was really curious to know about his Parkinson's-like symptoms, so we looked pretty closely in his genome for that kind of stuff. We found a few hints, but we couldn't tell him why he has symptoms like a tremor. And frankly, his history of drug abuse probably contributed to that, too,' Nathan Pearson, then research director of Cofactor Genomics which sequenced Osbourne's genome, told Scientific American in 2010. Does Parkinson's Disease Cause Death? Data on Parkinson's disease and mortality are inconsistent, with some studies suggesting that those with the condition, particularly an advanced or severe form, have about a 1.5 times higher death rate than the general population, according to the American Parkinson Disease Association. Parkinson's disease in combination with another disease or injury, such as a fall, ulcer or pneumonia, could also increase the likelihood of death. While uncurable, Parkinson's is considered a livable disease. Drugs that act on certain brain neurotransmitters, including dopamine —a hormone involved in movement—can help alleviate symptoms. Research on deep-brain stimulation, which was approved by the U.S. Food and Drug Administration for Parkinson's tremor in 1997, has shown the technology to be a highly effective treatment.
Yahoo
3 hours ago
- Yahoo
Real-time payments zoom ahead
This story was originally published on Payments Dive. To receive daily news and insights, subscribe to our free daily Payments Dive newsletter. Dive Brief: Second-quarter transaction volume for the Federal Reserve's young FedNow real-time payments system jumped 63% over the first quarter, to 2.1 million payments, the central bank said Wednesday. Meanwhile, second-quarter volume at the older private rival RTP network, operated by The Clearing House, rose 8% to 107 million payments, compared to the first quarter, according to its release on Thursday. Still, The Clearing House, owned by some of the world's biggest banks, accounts for the lion's share of real-time payments in the U.S., capturing 98% of the second-quarter activity. That private system processed $481 billion in payments during the second quarter, nearly tripling the amount it handled in the first quarter, according to its release. By contrast, the nascent FedNow system processed $245.8 billion in transactions for the second quarter, according to its statistics. Dive Insight: Payments systems worldwide have been moving to embrace real-time networks. The competing FedNow and RTP systems, like others around the globe, have the ability to move transactions in seconds, as opposed to days on less technologically advanced networks. Given that FedNow launched just two years ago in July 2023, it stands to reason that it's experiencing higher growth than the older rival RTP, which began in 2017. But professionals who follow the industry have still wondered out loud about slow progress for FedNow. 'Volume growth is 'middling' for FedNow,' Chicago payments industry consultant Peter Tapling said by email last week in commenting on the second-quarter results. 'From these low volume numbers, we'd like to see them doubling (or more) volume quarter over quarter.' A decade ago, the central bank and financial institutions had brainstormed together about bringing real-time payments to the U.S. Eventually, the banks moved on their own to launch RTP at The Clearing House, followed by the central bank deciding later to start a rival system. The Fed made the FedNow move when it became clear that smaller financial institutions were somewhat reluctant to join the real-time payments system operated by their larger competitors, including JPMorgan Chase, Bank of America, Capital One Financial and Barclays. In any case, there is some evidence that the launch of FedNow has spurred more activity on both systems. So far, FedNow has attracted participation from about 1,400 of the approximately 8,800 banks and credit unions in the U.S., according to the Fed's latest release. It also reported that the value of FedNow's average daily volume more than quintupled to $2.7 billion. While The Clearing House didn't provide an average daily volume value, it reported the average value of a payment passed over RTP surged during the quarter to about $4,000 for June, up from $842 in January. The value of the average payment on the FedNow network was much higher at $115,332 for the quarter. That average payment size for FedNow struck Tapling as high, leading him to conclude that a significant share of the Fed's system is in handling corporate transactions. Both FedNow and RTP have been gradually increasing the limit size for the payments they are willing to handle. Recommended Reading Fiserv exec talks real-time payments and challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
6 hours ago
- CNBC
How companies are using body heat sensors to make offices more efficient and hospitable
Butlr heat sensing tech provides insights into office space utilization. A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. As more and more employees return to the office, by choice or by force, large companies are more interested than ever in understanding how they use the space. The pandemic fundamentally changed how and where people work, and even in the return-to-office dynamic, there is a greater focus on how to best utilize and monetize office space, as well as make it more energy-efficient. To that end, some companies are using body heat. Butlr, a 6-year-old, San Francisco-based startup that was a spinoff of MIT Media Lab, leverages body temperature technology to understand how humans act and interact in the office without using cameras. In other words, it's anonymous. Sensors placed around the office space record the heat and then incorporate AI to look at every aspect of physical interactions. That includes occupancy, foot traffic, frequency and location of meetings, areas that are unoccupied or crowded and the impact on heating and cooling systems. But it goes beyond that. "By understanding how colleagues act and interact in the office while ensuring privacy, you can make it a place that is more productive, collaborative and aligned with the corporate culture – one where they look forward to being there," said Honghao Deng, CEO and co-founder of Butlr. "This can impact retention and performance, and you may even see attitudes shift from negative to positive." Companies use the data to make decisions about layout and design, retrofits, hybrid work schedules, maintenance, cleaning schedules and lease negotiations. CNBC's Property Play with Diana Olick covers new and evolving opportunities for the real estate investor, delivered weekly to your inbox. Subscribe here to get access today. The costs of so-called office fit-outs, or upgrades to spaces, are on the rise, according to a new report from JLL. "Increased focus on in-office attendance, employee experience and sustainability performance is leading focus on investing in high quality workspaces, with increased spend on materials and finishes and shifting cost profiles on many projects," according to the report. JLL also noted that those rising costs, as well as economic uncertainty, are contributing to hesitancy in CRE investment decisions. That has the potential to have long-term impacts on the overall workplace. Both raw material price increases and labor shortages are increasing overall construction costs across all regions. Still, more and more companies are pushing workers back to the office and solidifying flexible work arrangements into the culture. That flexible work paradigm, according to Deng, has more employers seeking data and insights into actual office usage. "You can think about this from both a cultural and a financial perspective," he said. In April, Butlr announced the completion of its latest investment round for a total of $75 million in funding to date. The company's clients span office, higher education and senior care and include names like Verizon, CBRE, Carrier and Compass Group. The company serves customers in North America, Europe and Asia.
